Correction to: Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO)

Hui Shao¹ · Vivian Fonseca² · Charles Stoecker¹ · Shuqian Liu¹ · Lizheng Shi¹

Published online: 16 May 2019
© Springer Nature Switzerland AG 2019

Correction to: PharmacoEconomics (2018) 36:1125–1134
<https://doi.org/10.1007/s40273-018-0662-1>

An error in the supplementary online appendix has been identified. In eTable 3, column (HbA1c), the parameter of “L1-HbA1c” should be 0.541.

The original article can be found online at <https://doi.org/10.1007/s40273-018-0662-1>.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s40273-019-00807-3>) contains supplementary material, which is available to authorized users.

✉ Lizheng Shi
lshi1@tulane.edu

¹ Department of Global Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street, Suite 1900, New Orleans, LA 70112, USA

² School of Medicine, Tulane University, New Orleans, LA, USA